The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
Open accessAbstract
BACKGROUND: Mineralocorticoid antagonists improve survival among patients with chronic, severe systolic heart failure and heart failure after myocardial infarction. We evaluated the effects of eplerenone in patients with chronic systolic heart failure and mild symptoms. METHODS: In this randomized, double-blind trial, we randomly assigned 2737 patients with New York Heart Association class II heart failure and an ejection fraction of no more than 35% to receive eplerenone (up to 50 mg daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure. RESULTS: The trial was stopped prematurely, according to prespecified rules, after a median follow-up period of 21 months. The primary outcome occurred in 18.3% of patients in the eplerenone group as compared with 25.9% in the placebo group (hazard ratio, 0.63; 95% confidence interval [CI], 0.54 to 0.74; P<0.001). A total of 12.5% of patients receiving eplerenone and 15.5% of those receiving placebo died (hazard ratio, 0.76; 95% CI, 0.62 to 0.93; P=0.008); 10.8% and 13.5%, respectively, died of cardiovascular causes (hazard ratio, 0.76; 95% CI, 0.61 to 0.94; P=0.01). Hospitalizations for heart failure and for any cause were also reduced with eplerenone. A serum potassium level exceeding 5.5 mmol per liter occurred in 11.8% of patients in the eplerenone group and 7.2% of those in the placebo group (P<0.001). CONCLUSIONS: Eplerenone, as compared with placebo, reduced both the risk of death and the risk of hospitalization among patients with systolic heart failure and mild symptoms. (Funded by Pfizer; ClinicalTrials.gov number, NCT00232180.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This effect was independent of diabetes status, and baseline HbA1c did not modify the effects on the primary outcome.531”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [531]
In the citing paper
“The mortality benefit of spironolactone in the RALES trial and eplerenone in the EMPHASIS-HF trial was consistent in T2DM and non-T2DM patients with HFrEF.158,159”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [159]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationPitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Self-citationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
Dickstein, K., Authors Task Force Members, Solal, A. C., Filippatos, G. S., McMurray, J. J. V., Ponikowski, P. P., Poole-Wilson, P. A., Strömberg, A., van Veldhuisen, D. J., Atar, D., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.08.005 · Cited by 3,535
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F. M., Remme, W. J., Cody, R. J., Castaigne, A., Pérez, A. J. P., Palensky, J., & Wittes, J. T. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Self-citationMcMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
Self-citationIvabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563
Self-citationHunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M. L., Konstam, M. A., MANCINI, D. M., Michl, K., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.013 · Cited by 1,398
Zannad, F. M., Alla, F., Dousset, B., Pérez, A. J. P., & Pitt, B. (2000) · Circulation · doi:10.1161/01.cir.102.22.2700 · Cited by 946
Self-citationCalculating the number needed to treat for trials where the outcome is time to an event
Altman, D. G., & Andersen, P. K. (1999) · BMJ · doi:10.1136/bmj.319.7223.1492 · Cited by 710
McKelvie, R. S., Yusuf, S., Pericak, D., Avezum, A., Burns, R. J., Probstfield, J., Tsuyuki, R. T., White, M., Rouleau, J., Latini, R., et al. (1999) · Circulation · doi:10.1161/01.cir.100.10.1056 · Cited by 692
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,004
Cardiovascular Effects of Aldosterone
Escoubet, B., Couffignal, C., Laisy, J.-P., Mangin, L., Chillon, S., Laouenan, C., Serfaty, J., Jeunemaı̂tre, X., Mentré, F., & Zennaro, M. (2013) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.113.000115 · Cited by 33
Ferreira, J. P., Mentz, R. J., Pizard, A., Pitt, B., & Zannad, F. M. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.814 · Cited by 32
Self-citationSpironolactone Dose in Heart Failure with Preserved Ejection Fraction: Findings from TOPCAT
Ferreira, J. P., Rosselló, X., Pocock, S., Rossignol, P., Claggett, B. L., Rouleau, J. L., Solomon, S. D., Pitt, B., Pfeffer, M. A., & Zannad, F. M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1909 · Cited by 32
Self-citationNguyen, M., Rumjaun, S., Lowe‐Jones, R., Ster, I. C., Rosano, G. M. C., Anderson, L., & Banerjee, D. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12796 · Cited by 32
Functional ACE2 deficiency leading to angiotensin imbalance in the pathophysiology of COVID-19
Cook, J. R., & Ausiello, J. C. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09663-z · Cited by 32
“Downstream off AT2, aldosterone also causes deleterious effects on the cardiovascular system as evidenced by the all-cause mortality benefit conferred by mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction [45, 46].”
BackgroundHsiao, F., Lin, C., Yu, C., Tung, Y., & Chu, P. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.794707 · Cited by 32
The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure
Voors, A. A., Dorhout, B., & van der Meer, P. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.797963 · Cited by 32
Mixed lineage kinase-3 prevents cardiac dysfunction and structural remodeling with pressure overload
Calamaras, T. D., Baumgärtner, R., Aronovitz, M. J., McLaughlin, A. L., Tam, K., Richards, D. A., Cooper, C., Li, N., Baur, W. E., Qiao, X., et al. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00029.2018 · Cited by 32
Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping
Dimond, M. G., Ibrahim, N. E., Fiuzat, M., McMurray, J. J. V., Lindenfeld, J. M., Ahmad, T., Bozkurt, B., Bristow, M. R., Butler, J., Carson, P. E., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.11.005 · Cited by 37
Self-citationWhen to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases
Kobayashi, M., Girerd, N., & Zannad, F. M. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae004 · Cited by 33
Self-citationContemporary Strategies in the Diagnosis and Management of Heart Failure
Dunlay, S. M., Pereira, N. L., & Kushwaha, S. S. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.01.004 · Cited by 30
PDE3 inhibition in dilated cardiomyopathy
Movsesian, M. A., Wever‐Pinzon, O., & Vandeput, F. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.09.001 · Cited by 31
Comparison of Agents That Affect Aldosterone Action
Tamargo, J. L., Solini, A., & Ruilope, L. M. (2014) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2014.04.005 · Cited by 31
McMurray, J. J. V., Anand, I. S., Díaz, R., Maggioni, A. P., O’Connor, C. M., Pfeffer, M. A., Solomon, S. D., Tendera, M., van Veldhuisen, D. J., Albizem, M. B., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs204 · Cited by 31
Self-citationLCZ696: a new paradigm for the treatment of heart failure?
Minguet, J., Sutton, G. L., Ferrero, C., Gomez, T., & Bramlage, P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1000300 · Cited by 31
“Data from multicenter, randomized, double-blinded clinical trials have provided the basis for the standard-of-care treatment for HF-REF [1,2,17-21].”
Rossignol, P., Dobre, D., Gregory, D., Massaro, J. M., Kiernan, M., Konstam, M. A., & Zannad, F. M. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.02.034 · Cited by 31
Self-citationSynthesis of annulated pyridines as inhibitors of aldosterone synthase (CYP11B2)
Martin, R. E., Lehmann, J., Alzieu, T., Lenz, M., Corrales, M. A. C., Aebi, J. D., Märki, H. P., Kuhn, B., Amrein, K. E., Mayweg, A. V. W., et al. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob00848h · Cited by 32
Nijst, P., Verbrugge, F. H., Martens, P., Bertrand, P. B., Dupont, M., Francis, G. S., Tang, W. H. W., & Müllens, W. (2017) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320317729919 · Cited by 31
“Exclusion criteria were (1) administration of intravenous diuretics before study inclusion; (2) mechanical ventilation; (3) inotropic or vasopressor support; (4) concurrent diagnosis of an acute coronary syndrome; (5) renal replacement therapy; or (6) ventricular assist devices, including the use of an intraaortic bal…”
BackgroundMethodErlandsson, F., Albayaty, M., Chialda, L., Ericsson, H., Amilon, C., Nelander, K., Jansson‐Löfmark, R., Wernevik, L. C., Kjaer, M., Bamberg, K., et al. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13562 · Cited by 30
Gender Differences in Ischemic Cardiomyopathy
Divoky, L., Maran, A., & Ramu, B. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0750-x · Cited by 31
Hyperkalaemia: aetiology, epidemiology, and clinical significance
Tromp, J., & van der Meer, P. (2019) · European Heart Journal Supplements · doi:10.1093/eurheartj/suy028 · Cited by 31
“0mEq/L were excluded at study inclusion.(26) In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), 6632 patients with acutemyocardial infarction complicated by left ventricular dysfunction and HF, incidence rates of hyperkalaemia were 15.”
BackgroundMethodNeurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure
Grosman‐Rimon, L., Billia, F., Wright, E., Carasso, S., Elbaz‐Greener, G., Kachel, E., Rao, V. A., & Cherney, D. Z. I. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09860-8 · Cited by 32
Crespo‐Leiro, M. G., Barge‐Caballero, E., Segovia, J., González‐Costello, J., López‐Fernández, S., García‐Pinilla, J. M., Bonet, L. A., Bagudá, J. D. J., Roig, E. S., Bayés‐Genís, A., et al. (2019) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2019.05.015 · Cited by 31
Jiang, X., Yao, J., & You, J. H. S. (2020) · JMIR mhealth and uhealth · doi:10.2196/17846 · Cited by 33
“68% for NYHA classes I, II, III, and IV, respectively) were estimated by the yearly all-cause mortality rate of each NYHA class, retrieved from the outcomes of the control group in a clinical trial of 2737 patients with heart failure with 4783 patient-years of follow-up [13,14].”
MethodRecent advances in pharmacological treatment of heart failure
Iacoviello, M., Palazzuoli, A., & Gronda, E. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13624 · Cited by 35
Guidetti, F., Lund, L. H., Benson, L., Hage, C., Musella, F., Stolfo, D., Mol, P. G. M., Flammer, A. J., Ruschitzka, F. T., Dahlström, U., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3049 · Cited by 33
The cardioprotective effects of mineralocorticoid receptor antagonists
van den Berg, T. N. A., Rongen, G. A. P. J. M., Fröhlich, G., Deinum, J., Hausenloy, D. J., & Riksen, N. P. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.006 · Cited by 31
2016 AHA/ACC Clinical Performance and Quality Measures for Prevention of Sudden Cardiac Death
Al‐Khatib, S. M., Yancy, C. W., Solis, P., Becker, L. B., Benjamin, E. J., Carrillo, R. G., Ezekowitz, J. A., Fonarow, G. C., Kantharia, B. K., Kleinman, M. E., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.09.933 · Cited by 31
Yang, P., Shen, W., Chen, X., Zhu, D., Xu, X., Wu, T., Xu, G., & Wu, Q. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09790-5 · Cited by 31
Kiuchi, M. G., Nolde, J. M., Villacorta, H., Carnagarin, R., Chan, J., Lugo‐Gavidia, L. M., Ho, J. K., Matthews, V. B., Dwivedi, G., & Schlaich, M. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102430 · Cited by 31
“Subjects in clinical trials tend to be younger and with healthier in comparison to daily clinical practice and therefore have a superior prognosis, with a twelve-monthly mortality rate of 5–10% in contemporary studies, although trial designs prevented very-low-risk subjects to get enrolled [27,28].”
BackgroundHeart failure with preserved ejection fraction.
Rigolli, M., & WHALLEY, G. A. (2013) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1671-5411.2013.04.011 · Cited by 30
Dı́ez, J. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0069-0 · Cited by 30
Papillon, J. P. N., Lou, C., Singh, A. K., Adams, C. M., Ksander, G. M., Beil, M. E., Chen, W., Leung-Chu, J., Fu, F., Gan, L., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01545 · Cited by 30
Choi, K. H., Choi, J., Jeon, E., Lee, G.-Y., Choi, D., Lee, H., Kim, J., Chae, S. C., Baek, S. H., Kang, S., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009806 · Cited by 29
Range of adiposity and cardiorenal syndrome
Pazos, F. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i8.322 · Cited by 32
Pharmacological interventions for heart failure in people with chronic kidney disease
Lunney, M., Ruospo, M., Natale, P., Quinn, R. R., Ronksley, P. E., Konstantinidis, I., Palmer, S. C., Tonelli, M. A., Strippoli, G. F., & Ravani, P. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012466.pub2 · Cited by 33
Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
Palanisamy, S., Hernandez, M. F., Chang, T. I., & Mahaffey, K. W. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00269-3 · Cited by 32
“Finally, the EMPHASIS-HF trial showed a reduced risk of cardiovascular death or hospitalization in patients with NYHA class II HFrEF and LVEF of 35% or less with eplerenone compared with standard of care [43].”
MethodSteroidal MRA Across the Spectrum of Renal Function
Ferreira, J. P., Pitt, B., McMurray, J. J. V., Pocock, S., Solomon, S. D., Pfeffer, M. A., Zannad, F. M., & Rossignol, P. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.06.010 · Cited by 31
Self-citationČerlinskaitė‐Bajorė, K., Lam, C. S. P., Sliwa, K. S., Adamo, M., ter Maaten, J. M., Léopold, V., Mebazaa, A., Davison, B. A., Edwards, C., Arrigo, M., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2882 · Cited by 30
Role of mineralocorticoid receptor in insulin resistance
Garg, R., & Adler, G. K. (2012) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283533955 · Cited by 32
Yandrapalli, S., Aronow, W. S., Mondal, P., & Chabbott, D. R. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.68813 · Cited by 29
Hayashi, T., Shibata, H., Kurihara, I., Yokota, K., Mitsuishi, Y., Ohashi, K., Murai‐Takeda, A., Jo, R., Ohyama, T., Sakamoto, M., et al. (2017) · International Heart Journal · doi:10.1536/ihj.16-649 · Cited by 30
“pcDNA MR (1-984) was subcloned into pGBKT7 vector as described previously.”
MethodAbdul-Rahim, A. H., MacIsaac, R. L., Jhund, P. S., Petrie, M. C., Lees, K. R., & McMurray, J. J. V. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.02.074 · Cited by 29
Self-citationRisk of Arrhythmic Death in Patients With Nonischemic Cardiomyopathy
Chrispin, J., Merchant, F. M., Lakdawala, N. K., Wu, K. C., Tomaselli, G. F., Navara, R., Torbey, E., Ambardekar, A. V., Kabra, R., Arbustini, E., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.05.064 · Cited by 29
Elshahat, A., Mansour, A., Ellabban, M., Diaa, A., Hassan, A., Fawzy, A., Saad, O. A., Abouelmagd, M. E., Eid, M., Elaraby, A. R., et al. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04103-7 · Cited by 29
“Both medications showed constant reductions in both mortality and morbidity across diverse subsets of HFrEF patients [4, 7, 26].”
BackgroundPană, M.-A., Boulmpou, A., İleri, Ç., Manzi, G., Golino, M., Ostojic, M., Galimzhanov, A. M., Busnatu, Ș., Mega, S., & Perone, F. (2025) · Medicina · doi:10.3390/medicina61020211 · Cited by 34
“Their ability to improve HF outcomes and their renal-protective effects have enhanced their position as one of the cornerstones of HFrEF treatment [19,92].”
Heart Failure in Very Old Adults
Forman, D. E., Ahmed, A., & Fleg, J. L. (2013) · Current Heart Failure Reports · doi:10.1007/s11897-013-0163-7 · Cited by 29
Bienvenu, L. A., Reichelt, M., Delbridge, L., & Young, M. (2013) · Clinical science · doi:10.1042/cs20130050 · Cited by 29
Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010
Gensch, C., Hoppe, U. C., Böhm, M., & Laufs, U. (2010) · Clinical Research in Cardiology · doi:10.1007/s00392-010-0270-3 · Cited by 29
Rao, K. K., Enriquez, J. R., de Lemos, J. A., Alexander, K. P., Chen, A. Y., McGuire, D. K., Fonarow, G. C., & Das, S. R. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.06.020 · Cited by 28
Dev, S., Hoffman, T. K., Kavalieratos, D., Heidenreich, P. A., Wu, W., Schwenke, D. C., & Tracy, S. J. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002493 · Cited by 29
“Survey and focus group and interview 3 (6)”
BackgroundInfluentialCarroll, R., Mudge, A., Suna, J. M., Denaro, C. P., & Atherton, J. J. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.084 · Cited by 29
“In contrast, only 42% received MRA (perhaps related to evolving evidence on indications for use during the study [24]) although most treated participants were on target dose at baseline.”
BackgroundJones, N. R., Roalfe, A. K., Adoki, I., Hobbs, R. F., & Taylor, C. J. (2018) · Systematic Reviews · doi:10.1186/s13643-018-0810-x · Cited by 29
The Limitations of Symptom-based Heart Failure Management
Papadimitriou, L., Moore, C. K., Butler, J., & Long, R. C. (2019) · Cardiac failure review · doi:10.15420/cfr.2019.3.2 · Cited by 30
Income level and inequality as complement to geographical differences in cardiovascular trials
Ferreira, J. P., Rossignol, P., Dewan, P., Lamiral, Z., White, W. B., Pitt, B., McMurray, J. J. V., & Zannad, F. M. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.08.019 · Cited by 30
Self-citationMineralocorticoid receptor antagonists in patients with chronic kidney disease
Cosimato, C., Agoritsas, T., & Mavrakanas, T. A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107701 · Cited by 29
Contemporary Management of Heart Failure in Patients With Diabetes
Shaw, J. A., & Cooper, M. E. (2020) · Diabetes Care · doi:10.2337/dc20-2173 · Cited by 29
Pieronne-Deperrois, M., Gueret, A., Djerada, Z., Crochemore, C., Harouki, N., Henry, J., Dumesnil, A., Larchevêque, M., do-Rego, J.-C., do Rego, J. L., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13219 · Cited by 29
Approaches towards tissue‐selective pharmacology of the mineralocorticoid receptor
Clarisse, D., Deng, L., Bosscher, K. D., & Lother, A. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15719 · Cited by 29
Volume Overload in Heart Failure
Houston, B. A., Kalathiya, R., Kim, D. A., & Zakaria, S. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.05.002 · Cited by 29
Bangalore, S., Kumar, S., & Messerli, F. H. (2012) · Congestive Heart Failure · doi:10.1111/chf.12011 · Cited by 29
Iqbal, J., Andrew, R., Cruden, N. L. M., Kenyon, C. J., Hughes, K. A., Newby, D. E., Hadoke, P. W. F., & Walker, B. R. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2049 · Cited by 29
Ueda, T., Kawakami, R., Nishida, T., Onoue, K., Soeda, T., Okayama, S., Takeda, Y., Watanabe, M., Kawata, H., Uemura, S., et al. (2015) · Circulation Journal · doi:10.1253/circj.cj-14-1203 · Cited by 29
Xie, W., Zheng, F., Song, X., Zhong, B., & Li, Y. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.12.010 · Cited by 28
“Sensitivity analysis included nine RCTs enrolling 30,878 patients in which there was a high background use of ACEI and/or ARB (N80%) [7, 21,22,25,26,30,31,33,38].”
BackgroundSpironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome
Verbrugge, F. H., Martens, P., Ameloot, K., Haemels, V., Penders, J., Dupont, M., Tang, W. H. W., Droogné, W., & Müllens, W. (2018) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2018.1455947 · Cited by 29
“improved survival and reduced heart failure readmissions with spironolactone in advanced and eplerenone in mild heart failure with reduced ejection fraction [4,5].”
BackgroundRossignol, P., Duarte, K., Girerd, N., Karoui, M., McMurray, J. J. V., Swedberg, K. B., van Veldhuisen, D. J., Pocock, S., Dickstein, K., Zannad, F. M., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1724 · Cited by 29
Self-citationPitt, B., & Rossignol, P. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.057 · Cited by 27
Self-citationNariai, T., Fujita, K., Mori, M., Katayama, S., Hori, S., & Matsui, K. (2012) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3182495543 · Cited by 28
Renin Inhibitors and Cardiovascular and Renal Protection: An Endless Quest?
Azizi, M., & Ménard, J. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6380-6 · Cited by 28
Antiarrhythmic Drug Therapy for Atrial Fibrillation
Sardar, M. R., Saeed, W., & Kowey, P. R. (2016) · Heart Failure Clinics · doi:10.1016/j.hfc.2015.08.017 · Cited by 28
Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer
Epstein, M., & Pitt, B. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1190333 · Cited by 28
Self-citationSalvador, A. M., Moss, M. E., Aronovitz, M. J., Mueller, K. B., Blanton, R. M., Jaffe, I. Z., & Alcaide, P. (2017) · Physiological Reports · doi:10.14814/phy2.13313 · Cited by 28
“MR antagonists reduce mortality in patients with HF with reduced ejection fraction (Pitt et al. 1999, 2003; Zannad et al. 2011).”
BackgroundFrankenstein, L., Seide, S. E., Täger, T., Jensen, K., Fröhlich, H., Clark, A. L., Seiz, M., Katus, H. A., Nee, P., Uhlmann, L., et al. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09832-y · Cited by 29
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Hojs, N. V., Bevc, S., Ekart, R., Piko, N., Petreski, T., & Hojs, R. (2021) · Pharmaceuticals · doi:10.3390/ph14060561 · Cited by 28
“Side effects impotence, menstrual irregularities) Hyperkalemia Hyperkalemia Unknown Hyperkalemia Hyperkalemia Important clinical studies in cardiovascular medicine RALES study [63] TOPCAT trial [64] ALBATROSS trial [65] Weinberger et al. [92] EPHESUS [93] EMPHASIS-HF [94] Montalescot et al. [97] None Ito et al. [112]I…”
BackgroundInfluentialBellis, A., Gioia, G. D., Mauro, C., Mancusi, C., Barbato, E., Izzo, R., Trimarco, B., & Morisco, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132968 · Cited by 28
Severino, P., D’Amato, A., Prosperi, S., Fanisio, F., Birtolo, L. I., Costi, B., Netti, L., Chimenti, C., Lavalle, C., Maestrini, V., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147650 · Cited by 30
“Over the past years multiple clinical studies failed to demonstrate a direct outcome improvement in HFpEF treated with RAAS inhibitors [167–171], while the positive role of βblockers [172], angiotensin receptor blockers (ARBs), and mineralocorticoid receptor antagonists (MRAs) [173], on mortality and morbidity reducti…”
BackgroundHeart failure and its treatment from the perspective of sympathetic nerve activity
Minatoguchi, S. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2021.11.016 · Cited by 27
Zahir, D., Bonde, A. N., Madelaire, C., Malmborg, M. W., Butt, J. H., Fosbøl, E. L., Gislason, G., Torp-Pedersen, C. T., Andersson, C., Rossignol, P., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2418 · Cited by 28
Self-citationReal world comparison of spironolactone and eplerenone in patients with heart failure
Pardo-Martínez, P., Barge‐Caballero, E., Bouzas‐Mosquera, A., Barge‐Caballero, G., Couto‐Mallón, D., Paniagua-Martín, M. J., Sagastagoitia-Fornie, M., Prada‐Delgado, Ó., Muñiz, J., Bonet, L. A., et al. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.12.027 · Cited by 28
DeFronzo, R. A., & Bakris, G. L. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14696 · Cited by 32
Harrington, J., Petrie, M. C., Anker, S. D., Bhatt, D. L., Jones, W. S., Udell, J. A., Hernandez, A. F., & Butler, J. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.2847 · Cited by 28
Woo, C. Y., Strandberg, E. J., Schmiegelow, M., Pitt, A. L., Hlatky, M. A., Owens, D. K., & Goldhaber‐Fiebert, J. D. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1804 · Cited by 29
Aldosterone, organ damage and dietary salt
Catena, C., Colussi, G., & Sechi, L. (2013) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12145 · Cited by 28
Lung capillary injury and repair in left heart disease: a new target for therapy?
Azarbar, S., & Dupuis, J. (2014) · Clinical Science · doi:10.1042/cs20130296 · Cited by 28
Kurobe, H., Hirata, Y., Matsuoka, Y., Sugasawa, N., Higashida, M., Nakayama, T., Maxfield, M. W., Yoshida, Y., Shimabukuro, M., Kitagawa, T., et al. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.05.002 · Cited by 28
Hasui, T., Ohyabu, N., Ohra, T., Fuji, K., Sugimoto, T., Fujimoto, J., Asano, K., Oosawa, M., Shiotani, S., Nishigaki, N., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.07.038 · Cited by 28
Smith, S. A., Hasan, A. K., Binkley, P. F., & Foraker, R. E. (2014) · Journal of Surgical Research · doi:10.1016/j.jss.2014.05.004 · Cited by 28
“[29] Zannad F, McMurray JJV, Krum H, et al.”
BackgroundRoffi, M., Patrono, C., Collet, J., Mueller, C. E., Valgimigli, M., Bax, J. J., Borger, M. A., Chew, D. P., Hasenfuss, G. P., Kjeldsen, K. P., et al. (2015) · Cited by 27
Casimiro‐Garcia, A., Piotrowski, D. W., Ambler, C. M., Arhancet, G. B., Banker, M. E., Banks, T., Boustany, C., Cai, C., Chen, X., Eudy, R. J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500206r · Cited by 28
n–3 Fatty Acids in Cardiovascular Disease
Swedberg, K. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1108375 · Cited by 28
Self-citationBozkurt, B., Rossignol, P., & Vassalotti, J. A. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3683 · Cited by 32
Michel Komajda, N., Böhm, M., BORER, J. S., Ford, I., Krum, H., Tase, A. G., Tavazzi, L., & Swedberg, K. B. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs127 · Cited by 27
Self-citationCurrent Challenges in the Management of Heart Failure
Michel Komajda, N. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0368 · Cited by 27
Phelan, D. M. J., Thavendiranathan, P., Collier, P. H., & Marwick, T. H. (2012) · Heart · doi:10.1136/heartjnl-2012-302178 · Cited by 27
Pathophysiological and Clinical Approach to Cirrhotic Cardiomyopathy
Páll, A., Czifra, Á., Vitális, Z., Papp, M., Paragh, G., & Szabó, Z. (2014) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld.2014.1121.233.apac · Cited by 27
Rosendorff, C., Rosendorff, C., Lackland, D. T., Allison, M., Aronow, W. S., Black, H. R., Blumenthal, R. S., Cannon, C. P., de Lemos, J. A., Elliott, W. J., et al. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.10.045 · Cited by 30
Täger, T., Fröhlich, H., Grundtvig, M., Seiz, M., Schellberg, D., Goode, K. M., Kazmi, S., Hole, T., Katus, H. A., Atar, D., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.01.109 · Cited by 27
“This number is lower when compared to data from hospitalized HF patients included in the US American Perspective database [5] but rather similar to other samples of patients with chronic HF [6, 7].”
BackgroundResultGaziano, L., Cho, K., Djoussé, L., Schubert, P. L., Galloway, A., Ho, Y.-L. A., Kurgansky, K. E., GAGNON, D. R., Russo, J. P., Angelantonio, E. D., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13429 · Cited by 26
Abdelhamid, M., Rosano, G. M. C., Metra, M., Adamopoulos, S. N., Böhm, M., Chioncel, O. D., Filippatos, G. S., Jankowska, E. A., Lopatin, Y. M., Lund, L. H., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2594 · Cited by 29
Lin, D. S., Lin, F., Lin, Y., Lee, J., & Lin, Y. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2740 · Cited by 27
Metadata
- Authors
- Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B.
- Affiliations
- Inserm (FR)
- Monash University (AU)
- University of Gothenburg (SE)
- Pfizer (United States) (US)
- London School of Hygiene & Tropical Medicine (GB)
- University of Michigan (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-06
- Volume
- 364
- Issue
- 1
- Pages
- 11-21
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2164705414
- Cited by
- 3,111
- References
- 27
- Citations by year
- 2026: 184 · 2025: 168 · 2024: 167 · 2023: 177 · 2022: 228 · 2021: 197 · 2020: 190 · 2019: 181 · 2018: 178 · 2017: 177 · 2016: 187 · 2015: 227 · 2014: 209 · 2013: 239 · 2012: 216
- FWCI
- 139.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- eplerenone, mineralocorticoid receptor antagonists, heart failure with reduced ejection fraction, mild symptoms, heart failure hospitalization, cardiovascular mortality, hyperkalemia, ejection fraction
- MeSH terms
- Eplerenone, Aged, Mineralocorticoid Receptor Antagonists, Cardiovascular Agents, Cardiovascular Diseases, Combined Modality Therapy, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Spironolactone, Proportional Hazards Models, Defibrillators, Implantable, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
